SEC Tracker
Get the app

Ultragenyx Pharmaceutical RARE

Ultragenyx Pharmaceutical reported a $118 million net loss

Form
10-Q
Filed
Importance
Notable
  1. Revenue: $173 million for the three months ended Sep 30, 2026
  2. Net loss: $118 million for the three months ended Sep 30, 2026
  3. Diluted EPS: -$1.16 for the three months ended Sep 30, 2026

Written from the 10-Q on EDGAR. Check the filing before you rely on it.

Open in the appGet the appView on EDGAR

Get an email when Ultragenyx Pharmaceutical files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Similar companies

Companies of similar size in SIC 2834 and related industry codes: the same peer list as the financial tables.

  1. Avidity Biosciences RNAM public float $3.4B, Jun 30, 2025
  2. PERRIGO PRGO public float $3.7B, Jun 27, 2025
  3. Vaxcyte PCVX public float $3.7B, Jun 30, 2025
  4. Rhythm Pharmaceuticals RYTM public float $3.8B, Jun 30, 2025
  5. Viking Therapeutics VKTX public float $3.0B, Jun 30, 2025